<DOC>
	<DOC>NCT02267863</DOC>
	<brief_summary>This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.</brief_summary>
	<brief_title>A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies</brief_title>
	<detailed_description>This is an open label, phase 1b dose escalation with two disease specific expansions, multicenter, safety, pharmacokinetic and pharmacodynamic study to determine the maximum tolerated dose (MTD) or appropriate dose if MTD not reached to identify the recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Male or female 18 years of age or older Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed Meet laboratory parameter requirements at study entry Pregnancy or breast feeding History of prior malignancy Autoimmune hemolytic anemia Acute Promyelocytic Leukemia Uncontrolled and clinically significant diseaserelated metabolic disorder Other serious illness or medical conditions Patients who have exhibited allergic reactions to compounds structurally similar to APTO253 HCl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>